Annual FCF
-$32.16 M
+$4.54 M+12.37%
December 31, 2023
Summary
- As of February 7, 2025, ONCT annual free cash flow is -$32.16 million, with the most recent change of +$4.54 million (+12.37%) on December 31, 2023.
- During the last 3 years, ONCT annual FCF has fallen by -$14.67 million (-83.85%).
- ONCT annual FCF is now -40305.00% below its all-time high of $80.00 thousand, reached on December 31, 2000.
Performance
ONCT Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$6.95 M
-$1.13 M-19.43%
September 30, 2024
Summary
- As of February 7, 2025, ONCT quarterly free cash flow is -$6.95 million, with the most recent change of -$1.13 million (-19.43%) on September 30, 2024.
- Over the past year, ONCT quarterly FCF has increased by +$485.00 thousand (+6.52%).
- ONCT quarterly FCF is now -124.83% below its all-time high of $28.00 million, reached on March 31, 2008.
Performance
ONCT Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$26.63 M
-$1.44 M-5.72%
September 30, 2024
Summary
- As of February 7, 2025, ONCT TTM free cash flow is -$26.63 million, with the most recent change of -$1.44 million (-5.72%) on September 30, 2024.
- Over the past year, ONCT TTM FCF has increased by +$2.00 million (+6.99%).
- ONCT TTM FCF is now -911.85% below its all-time high of -$2.63 million, reached on March 31, 2003.
Performance
ONCT TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
ONCT Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +12.4% | +6.5% | +7.0% |
| 3 y3 years | -83.8% | +36.6% | +31.8% |
| 5 y5 years | +18.3% | +36.6% | +31.8% |
ONCT Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -21.0% | +12.4% | -26.1% | +41.9% | -5.7% | +35.4% |
| 5 y | 5-year | -92.1% | +12.4% | -128.3% | +41.9% | -97.1% | +35.4% |
| alltime | all time | <-9999.0% | +31.0% | -124.8% | +56.0% | -911.9% | +45.9% |
Oncternal Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$6.95 M(+19.4%) | -$26.63 M(+5.7%) |
| Jun 2024 | - | -$5.82 M(-21.7%) | -$25.19 M(-12.0%) |
| Mar 2024 | - | -$7.44 M(+15.9%) | -$28.63 M(-11.0%) |
| Dec 2023 | -$32.16 M(-12.4%) | -$6.42 M(+16.4%) | -$32.16 M(-7.4%) |
| Sep 2023 | - | -$5.51 M(-40.5%) | -$34.75 M(-15.7%) |
| Jun 2023 | - | -$9.26 M(-15.6%) | -$41.20 M(+5.5%) |
| Mar 2023 | - | -$10.97 M(+21.9%) | -$39.07 M(+6.4%) |
| Dec 2022 | -$36.70 M(+38.0%) | -$9.00 M(-24.8%) | -$36.70 M(+7.0%) |
| Sep 2022 | - | -$11.97 M(+67.8%) | -$34.32 M(+19.4%) |
| Jun 2022 | - | -$7.13 M(-17.2%) | -$28.73 M(-1.6%) |
| Mar 2022 | - | -$8.61 M(+30.1%) | -$29.21 M(+9.9%) |
| Dec 2021 | -$26.59 M(+52.0%) | -$6.62 M(+3.7%) | -$26.59 M(+11.3%) |
| Sep 2021 | - | -$6.38 M(-16.1%) | -$23.88 M(+4.6%) |
| Jun 2021 | - | -$7.61 M(+27.1%) | -$22.83 M(+17.4%) |
| Mar 2021 | - | -$5.99 M(+53.0%) | -$19.44 M(+11.1%) |
| Dec 2020 | -$17.50 M(+4.5%) | -$3.91 M(-26.6%) | -$17.50 M(+5.2%) |
| Sep 2020 | - | -$5.33 M(+26.2%) | -$16.63 M(+9.9%) |
| Jun 2020 | - | -$4.22 M(+4.6%) | -$15.13 M(+12.0%) |
| Mar 2020 | - | -$4.04 M(+32.5%) | -$13.51 M(-19.3%) |
| Dec 2019 | -$16.75 M(-57.4%) | -$3.04 M(-20.5%) | -$16.75 M(-28.2%) |
| Sep 2019 | - | -$3.83 M(+47.2%) | -$23.32 M(-14.3%) |
| Jun 2019 | - | -$2.60 M(-64.2%) | -$27.20 M(-23.4%) |
| Mar 2019 | - | -$7.27 M(-24.4%) | -$35.51 M(-9.8%) |
| Dec 2018 | -$39.35 M(+67.7%) | -$9.62 M(+24.6%) | -$39.35 M(-0.3%) |
| Sep 2018 | - | -$7.72 M(-29.2%) | -$39.46 M(+12.4%) |
| Jun 2018 | - | -$10.90 M(-1.9%) | -$35.12 M(+19.6%) |
| Mar 2018 | - | -$11.11 M(+14.2%) | -$29.37 M(+25.2%) |
| Dec 2017 | -$23.46 M(+12.4%) | -$9.73 M(+188.5%) | -$23.46 M(+23.5%) |
| Sep 2017 | - | -$3.37 M(-34.6%) | -$18.99 M(-13.5%) |
| Jun 2017 | - | -$5.16 M(-0.9%) | -$21.95 M(+3.1%) |
| Mar 2017 | - | -$5.20 M(-1.1%) | -$21.29 M(+2.0%) |
| Dec 2016 | -$20.87 M(+4.1%) | -$5.26 M(-17.0%) | -$20.87 M(+0.3%) |
| Sep 2016 | - | -$6.33 M(+41.0%) | -$20.81 M(+7.0%) |
| Jun 2016 | - | -$4.49 M(-6.1%) | -$19.45 M(-3.4%) |
| Mar 2016 | - | -$4.78 M(-8.1%) | -$20.13 M(+0.4%) |
| Dec 2015 | -$20.04 M(-30.3%) | -$5.20 M(+4.6%) | -$20.04 M(+0.7%) |
| Sep 2015 | - | -$4.97 M(-3.7%) | -$19.90 M(-3.6%) |
| Jun 2015 | - | -$5.17 M(+10.0%) | -$20.64 M(-18.6%) |
| Mar 2015 | - | -$4.70 M(-7.2%) | -$25.37 M(-11.8%) |
| Dec 2014 | -$28.76 M(-34.6%) | -$5.06 M(-11.5%) | -$28.76 M(-8.3%) |
| Sep 2014 | - | -$5.72 M(-42.2%) | -$31.35 M(-14.5%) |
| Jun 2014 | - | -$9.90 M(+22.3%) | -$36.68 M(-3.8%) |
| Mar 2014 | - | -$8.09 M(+5.8%) | -$38.14 M(-13.3%) |
| Dec 2013 | -$44.00 M | -$7.65 M(-30.7%) | -$44.00 M(-5.2%) |
| Sep 2013 | - | -$11.04 M(-2.8%) | -$46.43 M(+5.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | -$11.36 M(-18.6%) | -$44.03 M(+8.2%) |
| Mar 2013 | - | -$13.95 M(+38.4%) | -$40.69 M(+9.2%) |
| Dec 2012 | -$37.25 M(+12.4%) | -$10.08 M(+16.7%) | -$37.25 M(+4.3%) |
| Sep 2012 | - | -$8.64 M(+7.7%) | -$35.72 M(+2.1%) |
| Jun 2012 | - | -$8.02 M(-23.7%) | -$34.99 M(+1.7%) |
| Mar 2012 | - | -$10.51 M(+22.9%) | -$34.41 M(+3.8%) |
| Dec 2011 | -$33.14 M(+8.2%) | -$8.55 M(+8.1%) | -$33.14 M(+27.7%) |
| Sep 2011 | - | -$7.91 M(+6.2%) | -$25.95 M(-2.7%) |
| Jun 2011 | - | -$7.44 M(-19.5%) | -$26.68 M(-9.7%) |
| Mar 2011 | - | -$9.24 M(+579.8%) | -$29.54 M(-3.5%) |
| Dec 2010 | -$30.62 M(-34.3%) | -$1.36 M(-84.2%) | -$30.62 M(-14.4%) |
| Sep 2010 | - | -$8.63 M(-16.3%) | -$35.76 M(-8.6%) |
| Jun 2010 | - | -$10.31 M(-0.2%) | -$39.10 M(-5.8%) |
| Mar 2010 | - | -$10.33 M(+59.0%) | -$41.53 M(-10.9%) |
| Dec 2009 | -$46.60 M(+699.3%) | -$6.50 M(-45.8%) | -$46.60 M(+0.0%) |
| Sep 2009 | - | -$11.97 M(-5.9%) | -$46.58 M(+0.9%) |
| Jun 2009 | - | -$12.73 M(-17.3%) | -$46.15 M(-6.3%) |
| Mar 2009 | - | -$15.39 M(+137.7%) | -$49.23 M(+744.4%) |
| Dec 2008 | -$5.83 M(-85.2%) | -$6.48 M(-43.9%) | -$5.83 M(-37.6%) |
| Sep 2008 | - | -$11.55 M(-27.0%) | -$9.35 M(+1.9%) |
| Jun 2008 | - | -$15.81 M(-156.5%) | -$9.17 M(+221.0%) |
| Mar 2008 | - | $28.00 M(-380.1%) | -$2.86 M(-92.7%) |
| Dec 2007 | -$39.37 M(+227.0%) | -$10.00 M(-12.1%) | -$39.37 M(+231.2%) |
| Sep 2007 | - | -$11.37 M(+19.7%) | -$11.89 M(+3.1%) |
| Jun 2007 | - | -$9.49 M(+11.6%) | -$11.53 M(-2.3%) |
| Mar 2007 | - | -$8.51 M(-148.7%) | -$11.79 M(-2.0%) |
| Dec 2006 | -$12.04 M(-66.3%) | $17.49 M(-258.8%) | -$12.04 M(-69.1%) |
| Sep 2006 | - | -$11.01 M(+12.7%) | -$38.93 M(+2.9%) |
| Jun 2006 | - | -$9.77 M(+11.6%) | -$37.83 M(+6.4%) |
| Mar 2006 | - | -$8.75 M(-6.9%) | -$35.56 M(-0.6%) |
| Dec 2005 | -$35.75 M(+112.3%) | -$9.40 M(-5.1%) | -$35.75 M(+7.9%) |
| Sep 2005 | - | -$9.91 M(+32.2%) | -$33.12 M(+16.0%) |
| Jun 2005 | - | -$7.50 M(-16.2%) | -$28.56 M(+41.1%) |
| Mar 2005 | - | -$8.95 M(+32.2%) | -$20.24 M(+20.2%) |
| Dec 2004 | -$16.84 M(+28.5%) | -$6.77 M(+26.5%) | -$16.84 M(+19.8%) |
| Sep 2004 | - | -$5.35 M(-749.2%) | -$14.06 M(+17.0%) |
| Jun 2004 | - | $824.00 K(-114.8%) | -$12.02 M(-25.0%) |
| Mar 2004 | - | -$5.55 M(+39.4%) | -$16.02 M(+22.3%) |
| Dec 2003 | -$13.11 M(+20.6%) | -$3.98 M(+20.3%) | -$13.11 M(+43.6%) |
| Sep 2003 | - | -$3.31 M(+4.1%) | -$9.12 M(+56.9%) |
| Jun 2003 | - | -$3.18 M(+20.9%) | -$5.81 M(+120.9%) |
| Mar 2003 | - | -$2.63 M | -$2.63 M |
| Dec 2002 | -$10.87 M(<-9900.0%) | - | - |
| Dec 2000 | $80.00 K(+77.8%) | - | - |
| Dec 1999 | $45.00 K | - | - |
FAQ
- What is Oncternal Therapeutics annual free cash flow?
- What is the all time high annual FCF for Oncternal Therapeutics?
- What is Oncternal Therapeutics annual FCF year-on-year change?
- What is Oncternal Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Oncternal Therapeutics?
- What is Oncternal Therapeutics quarterly FCF year-on-year change?
- What is Oncternal Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Oncternal Therapeutics?
- What is Oncternal Therapeutics TTM FCF year-on-year change?
What is Oncternal Therapeutics annual free cash flow?
The current annual FCF of ONCT is -$32.16 M
What is the all time high annual FCF for Oncternal Therapeutics?
Oncternal Therapeutics all-time high annual free cash flow is $80.00 K
What is Oncternal Therapeutics annual FCF year-on-year change?
Over the past year, ONCT annual free cash flow has changed by +$4.54 M (+12.37%)
What is Oncternal Therapeutics quarterly free cash flow?
The current quarterly FCF of ONCT is -$6.95 M
What is the all time high quarterly FCF for Oncternal Therapeutics?
Oncternal Therapeutics all-time high quarterly free cash flow is $28.00 M
What is Oncternal Therapeutics quarterly FCF year-on-year change?
Over the past year, ONCT quarterly free cash flow has changed by +$485.00 K (+6.52%)
What is Oncternal Therapeutics TTM free cash flow?
The current TTM FCF of ONCT is -$26.63 M
What is the all time high TTM FCF for Oncternal Therapeutics?
Oncternal Therapeutics all-time high TTM free cash flow is -$2.63 M
What is Oncternal Therapeutics TTM FCF year-on-year change?
Over the past year, ONCT TTM free cash flow has changed by +$2.00 M (+6.99%)